FOXM1, whose transcriptional network includes DNA repair genes [255], has been reported to promote ovarian cancer resistance to taxanes (e.g., paclitaxel and docetaxel), platinum-based drugs (e.g., cisplatin and carboplatin), and PARPi (e.g., olaparib and niraparib). Here, FOXM1 is linked to ovarian carcinoma.